STOCK TITAN

Zymeworks' Paul Andrew Moore sells 39,741 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Zymeworks Inc. (ZYME) Chief Scientific Officer Paul Andrew Moore exercised options for 25,000 shares on November 13, 2026, at an exercise price of $5.82 per share; his reported option position afterward covered 175,000 shares. He also sold 39,741 shares in three entries at weighted-average prices of $26.14, $26.09 and $26.04 per share. No Rule 10b5-1 plan is reported.

Insider Moore Paul Andrew
Role Chief Scientific Officer
Sold 39,741 shs ($1.04M)
Approx. gross sale proceeds $1.04M
Approx. exercise cost $146K
Share of Position Sold 54.1%
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F4 25,000 $0.00 $0.00
Exercise Common Stock 25,000 $5.82 $146K
Sale Common Stock F1 7,367 $26.14 $193K
Sale Common Stock F2 7,374 $26.09 $192K
Sale Common Stock F3 25,000 $26.04 $651K
Holdings After Transaction: Stock Option (Right to Buy) — 175,000 options (Direct); Common Stock — 33,756 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy), 200,000 to 175,000 options (Direct); Common Stock, 48,497 to 33,756 shares (Direct)
Footnotes (4)
  1. F1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.07 to $26.21, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.05 to $26.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.95 to $26.11, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  4. F4. Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
Shares sold 39,741 shares Three sale entries on November 13, 2026
Shares acquired through option exercise 25,000 shares November 13, 2026
Option exercise price $5.82 per share Options exercised on November 13, 2026
Reported option position after exercise 175,000 shares Shares covered by options after the November 13, 2026 transaction
Weighted-average sale price $26.14 per share 7,367-share sale entry on November 13, 2026
Weighted-average sale price $26.09 per share 7,374-share sale entry on November 13, 2026
Weighted-average sale price $26.04 per share 25,000-share sale entry on November 13, 2026
weighted average price financial
"price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
equal monthly installments technical
"remainder of underlying shares in 36 equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did ZYME's chief scientific officer sell?

Paul Andrew Moore sold 39,741 Zymeworks shares on November 13, 2026, in three entries at weighted-average prices of $26.14, $26.09 and $26.04 per share. No Rule 10b5-1 plan is reported.

What were the transaction-price ranges for Paul Moore's ZYME sales?

The 7,367-share entry averaged $26.14, with transaction prices from $26.07 to $26.21; the 7,374-share entry averaged $26.09, with prices from $26.05 to $26.15; and the 25,000-share entry averaged $26.04, with prices from $25.95 to $26.11. Each range is inclusive.

How do Paul Moore's Zymeworks stock options vest?

The options vest with 25% of underlying shares on the first anniversary of the grant date, and the remainder in 36 equal monthly installments on the last day of the month following the first anniversary of the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Moore Paul Andrew

(Last)(First)(Middle)
C/O ZYMEWORKS INC.
108 PATRIOT DRIVE, SUITE A

(Street)
MIDDLETOWN DELAWARE 19709

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/13/2026M25,000A$5.8273,497D
Common Stock11/13/2026S7,367D$26.14(1)66,130D
Common Stock11/13/2026S7,374D$26.09(2)58,756D
Common Stock11/13/2026S25,000D$26.04(3)33,756D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$5.8211/13/2026M25,000 (4)07/17/2032Common Stock25,000$0175,000D
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.07 to $26.21, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.05 to $26.15, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.95 to $26.11, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
4. Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
Remarks:
/s/ Catherine Graham, Attorney-in-Fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading